THERAPEUTIC POTENTIAL OF KAPPA-PVIIA

Information

• Research Project
• 6210306

• ApplicationId

  6210306

• Core Project Number

  R43AI046810

• Full Project Number

  1R43AI046810-01A1

• Serial Number

  46810

• FOA Number

• Sub Project Id

• Project Start Date

  9/1/2000 - 24 years ago

• Project End Date

  2/28/2002 - 22 years ago

• Program Officer Name

  PROGRAIS, LAWRENCE J.

• Budget Start Date

  9/1/2000 - 24 years ago

• Budget End Date

  2/28/2002 - 22 years ago

• Fiscal Year

  2000

• Support Year

  1

• Suffix

  A1

• Award Notice Date

  8/14/2000 - 24 years ago

Organizations

• COGNETIX, INC.

The specific aim of this proposal is to determine the therapeutic potential of the Conus peptide kappa-PVIIA. We intend in Phase I to examine the ability of the peptide to relax electrically stimulated or drug-induced contractions in isolated rat tissue. The ability of the peptide to relax the target tissue when administered intravenously or direct to the target tissue will also be assessed in anaesthetized rats. PROPOSED COMMERCIAL APPLICATION: We believe the kappa-PVIIA peptide will offer a novel treatment for certain disorders with none of the debilitating side-effects experienced with other similarly acting therapeutics. The peptide can be administered direct to the tissue effectively lowering the systemic dose.

IC Name

• Activity

  R43

• Administering IC

  AI

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  99700

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:99700\

• Funding Mechanism

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  COGNETIX, INC.

• Organization Department

• Organization DUNS

• Organization City

  SALT LAKE CITY

• Organization State

  UT

• Organization Country

  UNITED STATES

• Organization Zip Code

  84108

• Organization District

  UNITED STATES